Biopsies taken during surgery for carpal tunnel syndrome, a condition that affects a wrist nerve, may help with early detection of transthyretin cardiac…
News
Although mutations that cause hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) most frequently lead to nerve damage, they can also cause heart damage and other…
Enrollment is open in a post-marketing clinical trial designed to investigate whether long-term treatment with Attruby (acoramidis) can reverse heart disease-related changes in people…
A specific genetic variant may have contributed to signs of severe liver problems observed in a few patients given nexiguran ziclumeran (nex-z), an investigational gene-editing…
Regulatory authorities in the European Union (EU) have recommended approval of Tafamidis Accord, a generic version of Vyndaqel (tafamidis), an approved treatment for adults with hereditary…
A real-world study in Spain comparing two similar medications for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) showed greater benefits with the infusion therapy…
Women with transthyretin amyloid cardiomyopathy (ATTR-CM) had worse outcomes than men in a new study, but the gap may reflect differences in age and…
HATTR-PN
NewsCell stress may play key role in triggering hATTR-PN
A type of cell damage called oxidative stress may be key to the development of disease symptoms in people who carry the most common TTR…
Long-term treatment with the experimental therapy candidate cliramitug safely and effectively reduces toxic clumps of the transthyretin (TTR) protein and heart damage markers in…
Measuring blood levels of a protein called neurofilament light chain (NfL) may help identify nerve damage in people with hereditary transthyretin amyloidosis with polyneuropathy…
Recent Posts
- Weighing the pros and cons of participating in a clinical trial
- Wrist biopsy may aid in early detection of heart disease
- Study links hATTR-PN mutations to symptoms beyond nerve damage
- Navigating the risk of falls with hATTR amyloidosis
- Trial evaluates drug’s potential to reverse ATTR-CM heart damage